Executive Summary

US Healthcare trends

- Funding for VC-backed Healthcare companies in US raised $6.4B in 197 deals.
- Compared to Q1'20, the number of deals closed in Q2'20 decreased by 2% from 200 to 197.
- A total of $2.6 was raised this quarter through 14 mega-rounds*, making up 40% of total deal dollars raised in Q2'20.
- Deals of $100M or more in value.

US Healthcare places

- The top five Healthcare regions in terms of dollars raised were New England, Silicon Valley, San Diego, New York Metro, and DC/Metroplex.
- In Q2'20, New England raised $2.2B through 45 deals and is the leading region this quarter in terms of dollars raised. There were 7 mega-rounds in New England.
- Silicon Valley followed in second place, raising $1.2B across 34 deals.

US Healthcare industries

- Of the $6.4B raised in Q2'20, $2.7B was invested in the Biotechnology subsector while $1.4B was invested in the Drug Development industry.
- Compared to the prior quarter, the Biotechnology subsector saw a 7% decrease in funding.
- The Drug Development industry outperformed Medical Devices & Equipment in deal value, raising a total of $1.4B in 30 deals.

US Healthcare movers and shakers

- SOSV was the most active investor this quarter, investing in a total of 14 Healthcare deals.
- There were 14 Healthcare IPOs in Q2'20 raising approximately $2.4B.

Global healthcare trends

- Globally, dollars invested increased to $10.7B in Q2'20, while the number of deals increased from 427 in Q1'20 to 507 in Q2'20.
- In Q2'20, 232 deals closed in North America, followed by 159 deals in Asia, and 114 deals in Europe.
- North America raised $6.5B this quarter, while Europe raised $1.6B and finally Asia raised $2.6B.

Source: PwC/CB Insights MoneyTree™ Report Q2 2020
US Healthcare trends – Q2 2020
8-quarter Healthcare financing trends

Healthcare deal activity remained relatively consistent in Q2'20

- Dollars invested in US Healthcare increased slightly quarter to quarter from $6.3B in Q1'20 to $6.4B in Q2'20.
- Deal numbers have decreased by 2% from the prior quarter, with 197 deals closing in Q2'20. The average deal value increased from $31.6M in Q2'20 to $32.3M in Q2'20.
- Compared to the same quarter in FY’19, dollars invested increased 31% while the the number of deals decreased by 11% in Q2'20.
US Healthcare deal share by stage

“Other” stage companies concentrated majority of the deals

- **Other stage** deals had the largest share by stage in Q2’20, making up 36% of total dollars raised.
- **Later stage** deals continue to have the lowest share by stage in Q2’20, making up 8% of total dollars raised.

Source: PwC/CB Insights MoneyTree™ Report Q2 2020
Median US deal size by stage
Median deal size increased across all stages in Q2’20

- Median deal size for **later stage** companies saw a significant increase this quarter to $65.0M.
- **Seed stage** companies median deal size saw an increase this quarter, going from $2.5M in Q1’20 to $3.1M in Q2’20.
- **Early stage** companies median deal size saw an increase this quarter, going from $8.8M in Q1’20 to $20.0M in Q1’20.
- **Expansion stage** companies median deal size saw an increase this quarter, going from $35.0M in Q1’20 from $45.0M in Q2’20.

Source: PwC/CB Insights MoneyTree™ Report Q2 2020
Healthcare sector trends
Biotechnology related industries raised $5.3 billion

- A total of $5.3B invested into Biotechnology related industries in Q2'20, which represents a 7% increase from Q1'20, and deals remained flat quarter over quarter with 132 deals in Q1'20 and 131 deals in Q2'20.
- The Medical Devices & Equipment related industries decreased quarter over quarter to $847M in funding, but saw a 15% increase in number of deals from Q2'20.
- Other Healthcare related industries decreased significantly quarter over quarter to $185M in funding and number of deals decreased by 43% from Q2'20.

Source: PwC/CB Insights MoneyTree™ Report Q2 2020
Regional Healthcare trends
New England led in dollars invested and deal activity in Q2’20

- **New England** surpassed Silicon Valley and led in terms of dollars invested in Q2’20, with $2.2B raised this quarter through 45 deals. Of the 45 deals closed in Silicon Valley, **7 were mega-rounds**, raising a total of **$932M**.
- **Silicon Valley** followed behind and saw a **52%** decrease in funding to **$1.2B** when compared to the prior quarter. Number of deals closed also decreased, with **34** deals closing in Q2’20 compared to 49 deals in Q1’20.
- **New England** held **34% of the US Healthcare market share** for total deal dollars invested in Q2’20, while **Silicon Valley** accounted for **19%** of total deal dollars. Together, both regions accounted for **53%** total deal dollars in the country this quarter.

**Percentage change in dollars invested Q2’20/Q1’20**

- **New England**: 34%
- **Silicon Valley**: 51%
Regional Healthcare trends (continued)

Changes in other US regions:

- San Diego ended in third place in terms of number of deals, raising $875M through 24 deals in Q2’20, a 139% increase in dollars raised from the prior quarter.
- Of the 24 deals closed in San Diego, 2 were a mega-rounds, raising a total of $310M.
- San Diego held 14% of the US Healthcare market share for total deal dollars invested in Q2’20.

Percentage change in dollars invested Q2’20/Q1’20

![Map showing San Diego's increase in healthcare investments](image-url)
US Healthcare mega-rounds

Mega-round financing decreased this quarter, in both dollars invested and number of deals

- US Healthcare mega-round financing raised $2.6B in Q2’20, which was a 7% decrease from the mega-round funding in the prior quarter. Mega-round activity also decreased, with 14 deals closing in Q2’20 compared to 19 deals closing in Q1’20.
- Dollars raised from mega-round deals made up 40% of the total dollars raised in Q2’20.
- The average size of a mega-round deal was $182M in Q2’20, which is 26% greater than the $145M average mega-round deal size from the past quarter.

Source: PwC/CB Insights MoneyTree™ Report Q2 2020
Top five US Healthcare industries over the last five quarters

**Trends:**

- The **Biotechnology subsector** continues to lead the Healthcare industry in Q2’20 in terms of dollars invested, raising $2.7B, a 7% decrease from the $2.9B raised in Q1’20. Out of the 62 deals, closed, 6 were a mega-round deals which contributed $1.2B to the dollars invested in this quarter.

- The **Drug Development** industry outperformed the **Medical Devices & Equipment** industry this quarter in dollars invested, with $1.4B dollars invested. $675M of the total $1.4B invested came from 4 mega-round deals.

- The **Medical Devices & Equipment** industry raised $847M, a decrease of 1% from Q1’20, in terms of dollars invested. There was 1 mega-round deal in this industry, contributing $100M of the dollars invested.

---

**Source:** PwC/CB Insights MoneyTree™ Report Q2 2020
Q2’20 Deep dive
Biotechnology related industries

“The pandemic has not significantly impacted the healthcare financings trend. The number of deals remained stable compared to the past couple of quarters and the dollars invested have not been this high since Q2’2018.”

– Ousmane Caba, Life Science Partner at PwC

Largest Biotechnology and related industries deals in Q2’20:

- Sana Biotechnology: $481M
- Pionyr Immunotherapeutics: $275M
- Everest Medicines: $260M
- Atea Pharmaceuticals: $215M
- Erasca: $200M

Decrease in funding for Biotechnology subsector compared to Q1’20: 7%

Source: PwC/CB Insights MoneyTree™ Report Q2 2020
US Healthcare – Top five regions by deal value in Q2’20

- **New England**
  - 45 Deals
  - Avg. Deal Size: $48M
  - Total Deal Value: $2,166M

- **Silicon Valley**
  - 34 Deals
  - Avg. Deal Size: $36M
  - Total Deal Value: $1,226M

- **San Diego**
  - 24 Deals
  - Avg. Deal Size: $36M
  - Total Deal Value: $875M

- **New York Metro**
  - 18 Deals
  - Avg. Deal Size: $24M
  - Total Deal Value: $439M

- **DC/Metroplex**
  - 13 Deals
  - Avg. Deal Size: $24M
  - Total Deal Value: $307M

Source: PwC/CB Insights MoneyTree™ Report Q2 2020
<table>
<thead>
<tr>
<th>Region</th>
<th>Amount</th>
<th>Source</th>
</tr>
</thead>
<tbody>
<tr>
<td>AK/HI/PR</td>
<td>N/A</td>
<td>PwC/CB Insights MoneyTree™ Report Q2 2020</td>
</tr>
<tr>
<td>Northwest</td>
<td>$680M</td>
<td></td>
</tr>
<tr>
<td>North Central</td>
<td>$95M</td>
<td></td>
</tr>
<tr>
<td>Midwest</td>
<td>$103M</td>
<td></td>
</tr>
<tr>
<td>New York Metro</td>
<td>$439M</td>
<td></td>
</tr>
<tr>
<td>Philadelphia Metro</td>
<td>$159M</td>
<td></td>
</tr>
<tr>
<td>New England NY</td>
<td>$2,166M</td>
<td></td>
</tr>
<tr>
<td>DC/Metroplex</td>
<td>$307M</td>
<td></td>
</tr>
<tr>
<td>Upstate NY</td>
<td>$2M</td>
<td></td>
</tr>
<tr>
<td>North Central</td>
<td>$95M</td>
<td></td>
</tr>
<tr>
<td>Midwest</td>
<td>$103M</td>
<td></td>
</tr>
<tr>
<td>South Central</td>
<td>$3M</td>
<td></td>
</tr>
<tr>
<td>Silicon Valley</td>
<td>$1,226M</td>
<td></td>
</tr>
<tr>
<td>Sacramento/N. Cal N/A</td>
<td>N/A</td>
<td></td>
</tr>
<tr>
<td>Southwest</td>
<td>$20M</td>
<td></td>
</tr>
<tr>
<td>CO</td>
<td>$22M</td>
<td></td>
</tr>
<tr>
<td>Texas</td>
<td>$48M</td>
<td></td>
</tr>
<tr>
<td>LA/Orange County</td>
<td>$167M</td>
<td></td>
</tr>
<tr>
<td>San Diego</td>
<td>$875M</td>
<td></td>
</tr>
</tbody>
</table>
8-quarter financing trend – New England
Dollars raised and number of deals increased Q2’20

- New England, in Q2’20, raised $2.2B in 45 deals, compared to $1.5B in 41 deals in Q1’20.
- Compared to the same quarter in FY’19, dollars invested increased 130% and the number of deals increased 13% in Q2’20.
- The region raised $932M through 7 mega-rounds. The dollars invested in mega-round deals made up 42% of the total dollars raised in the region this quarter.

Source: PwC/CB Insights MoneyTree™ Report Q2 2020
Dollars invested in Silicon Valley decreased this quarter to $1.2B

- In Silicon Valley, Healthcare financing raised $1.2B in Q2’20, which was a 52% decrease from the funding in the prior quarter. Mega-round activity decreased with 3 deals closing in Q2’20, compared to 9 deals in Q1’20.
- The average size of a mega-round deal was $189M in Q2’20, compared to the $165M average mega-round deal size in Q2’20.

Source: PwC/CB Insights MoneyTree™ Report Q2 2020
## US – Top 10 states by deal value in Q2’20

| 1. | CA | $2,268M | 66 Deals, Avg. Deal Size: $34M |
| 2. | MA | $1,990M | 42 Deals, Avg. Deal Size: $47M |
| 3. | WA | $614M | 5 Deals, Avg. Deal Size: $123M |
| 4. | NY | $380M | 13 Deals, Avg. Deal Size: $29M |
| 5. | MD | $234M | 11 Deals, Avg. Deal Size: $21M |
| 6. | CT | $185M | 4 Deals, Avg. Deal Size: $46M |
| 7. | PA | $152M | 5 Deals, Avg. Deal Size: $30M |
| 8. | MN | $75M | 5 Deals, Avg. Deal Size: $15M |
| 9. | VA | $73M | 2 Deals, Avg. Deal Size: $37M |
| 10. | MI | $48M | 3 Deals, Avg. Deal Size: $16M |

Source: PwC/CB Insights MoneyTree™ Report Q2 2020
US Healthcare movers and shakers – Q2 2020
## Largest Healthcare deals in Q2’20

<table>
<thead>
<tr>
<th>Company</th>
<th>Location</th>
<th>Industry</th>
<th>Stage of funding</th>
<th>$ Value of deal</th>
<th>Select investors</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>1 Sana Biotechnology</strong></td>
<td>Seattle, WA</td>
<td>Biotechnology</td>
<td>$481M</td>
<td></td>
<td>Alaska Permanent Fund; Altitude Life Science Ventures; Amity Ventures; ARCH Venture Partners; Baillie Gifford &amp; Co.; Bezos Expeditions</td>
</tr>
<tr>
<td><strong>2 Pionyr</strong></td>
<td>South San Francisco, CA</td>
<td>Drug Discovery</td>
<td>$275M</td>
<td></td>
<td>Gilead Sciences</td>
</tr>
<tr>
<td><strong>3 Everest Medicines</strong></td>
<td>New York, NY</td>
<td>Drug Development</td>
<td>$260M</td>
<td></td>
<td>CBC Group; China Reform Holdings Corporation; Cormorant Capital; Dechong Capital; HBM Healthcare Investments</td>
</tr>
<tr>
<td><strong>4 Atea Pharmaceuticals</strong></td>
<td>Boston, MA</td>
<td>Biotechnology</td>
<td>$215M</td>
<td></td>
<td>Adage Capital Management; Ally Bridge Group; Bain Capital; Cormorant Asset Management; Morningside Venture Capital</td>
</tr>
<tr>
<td><strong>5 Erasca</strong></td>
<td>San Diego, CA</td>
<td>Drug Discovery</td>
<td>$200M</td>
<td></td>
<td>ARCH Venture Partners; City Hill Ventures; Colt Ventures; Cormorant Asset Management; EDBI; Invus Group; LifeSci Venture Partners; Terra Magnum Capital Partners</td>
</tr>
<tr>
<td><strong>6 Orca Bio</strong></td>
<td>Menlo Park, CA</td>
<td>Biotechnology</td>
<td>$192M</td>
<td></td>
<td>+ND Capital; 8VC; Data Collective; Illinois Municipal Retirement Fund; Kaiser Permanente; Lightspeed Venture Partners; Mubadala Investment Co</td>
</tr>
<tr>
<td><strong>7 C4 Therapeutics</strong></td>
<td>Watertown, MA</td>
<td>Drug Development</td>
<td>$150M</td>
<td></td>
<td>3E Bioventures; Adage Capital Management; Axil Capital; Bain Capital; Cobro Ventures</td>
</tr>
</tbody>
</table>

Source: PwC/CB Insights MoneyTree™ Report Q2 2020
<table>
<thead>
<tr>
<th>Investor</th>
<th>Deals</th>
<th>Select investments</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 SOSV</td>
<td>14</td>
<td>Opentrons; DtoR; Catalog Technologies; Prellis Biologics; Sun Genomics; Convalesce; Protera; Dalton Bioanalytics</td>
<td>Princeton, NJ</td>
</tr>
<tr>
<td>2 Polaris Partners</td>
<td>8</td>
<td>Suneva Medical; SQZ Biotech; Navitior Pharmaceuticals; Pandion Therapeutics; QurAlis; Glympse Bio</td>
<td>Boston, MA</td>
</tr>
<tr>
<td>3 Google Ventures</td>
<td>7</td>
<td>SQZ Biotech; Aledade; Cerevance; Accent Therapeutics; Verve Therapeutics</td>
<td>Mountain View, CA</td>
</tr>
<tr>
<td>4 ARCH Venture Partners</td>
<td>7</td>
<td>Nutcracker Therapeutics; Erasca; Verve Therapeutics; Aspen Neuroscience; ROME Therapeutics; Autobahn Therapeutics</td>
<td>Chicago, IL</td>
</tr>
<tr>
<td>5 Alexandria Venture Investments</td>
<td>6</td>
<td>Yumanity Therapeutics; Tara Biosystems; 3D Bio Holdings; Nitrome Biosciences; MOMA Therapeutics</td>
<td>Pasadena, CA</td>
</tr>
</tbody>
</table>

Source: PwC/CB Insights MoneyTree™ Report Q2 2020
## Healthcare IPOs in Q2’20

### Top 10 IPOs

<table>
<thead>
<tr>
<th>Company</th>
<th>Amount</th>
<th>Location</th>
<th>Industry</th>
</tr>
</thead>
<tbody>
<tr>
<td>Legend Biotech</td>
<td>$424M</td>
<td>Piscataway, NJ</td>
<td>Biotechnology</td>
</tr>
<tr>
<td>FORMA Therapeutics</td>
<td>$278M</td>
<td>Watertown, MA</td>
<td>Drug Discovery</td>
</tr>
<tr>
<td>Avidity Biosciences</td>
<td>$259M</td>
<td>La Jolla, CA</td>
<td>Biotechnology</td>
</tr>
<tr>
<td>Vaxcyte</td>
<td>$224M</td>
<td>Foster City, CA</td>
<td>Biotechnology</td>
</tr>
<tr>
<td>Akouos</td>
<td>$213M</td>
<td>Boston, MA</td>
<td>Drug Development</td>
</tr>
<tr>
<td>Generation Bio</td>
<td>$200M</td>
<td>Cambridge, MA</td>
<td>Drug Delivery</td>
</tr>
<tr>
<td>Zenthalis Pharmaceuticals</td>
<td>$165M</td>
<td>New York, NY</td>
<td>Drug Discovery</td>
</tr>
<tr>
<td>Inari Medical</td>
<td>$156M</td>
<td>Irvine, CA</td>
<td>Medical Devices &amp; Equipment</td>
</tr>
<tr>
<td>Pliant Therapeutics</td>
<td>$144M</td>
<td>South San Francisco, CA</td>
<td>Biotechnology</td>
</tr>
<tr>
<td>ORIC Pharmaceuticals</td>
<td>$120M</td>
<td>South San Francisco, CA</td>
<td>Drug Discovery</td>
</tr>
</tbody>
</table>

Source: PwC/CB Insights MoneyTree™ Report Q2 2020
Global Healthcare comparisons for Q2’20

$6.5B
232 Deals

$1.6B
114 Deals

$2.6B
159 Deals

Global Total
$10.7B
507 Deals

Source: PwC/CB Insights MoneyTree™ Report Q2 2020
Europe received an increase in funding in Q2’20, with $1.6B in total deal value this quarter.

- Dollars invested in Europe increased quarter to quarter from $864M in Q1’20 to $1.6B in Q2’20, an 88% increase.
- Deal numbers also increased quarter to quarter, with 81 deals closing in Q1’20 and 114 deals closing in Q2’20. The average deal value was $14.2M in Q2’20.
8-quarter financing trend – Asia

Number of deals and dollars invested increased in Asia
• Asia saw $2.6B invested across 159 healthcare deals in Q2’20.
• Dollars invested in Asia doubled quarter to quarter from $1.3B in Q1’20 to $2.6B in Q2’20.
• Deal numbers have increased by 47% from the prior quarter, with 159 deals closing in Q2’20 compared to 108 deals closing in Q1’20.

Source: PwC/CB Insights MoneyTree™ Report Q2 2020
# US States – Full listing of Q2 2020 deals and investments

<table>
<thead>
<tr>
<th>State</th>
<th>$M</th>
<th>#Deals</th>
<th>State</th>
<th>$M</th>
<th>#Deals</th>
<th>State</th>
<th>$M</th>
<th>#Deals</th>
</tr>
</thead>
<tbody>
<tr>
<td>California</td>
<td>2,268</td>
<td>66</td>
<td>Louisiana</td>
<td>2</td>
<td>1</td>
<td>Pennsylvania</td>
<td>152</td>
<td>5</td>
</tr>
<tr>
<td>Colorado</td>
<td>22</td>
<td>2</td>
<td>Maryland</td>
<td>234</td>
<td>11</td>
<td>Texas</td>
<td>48</td>
<td>7</td>
</tr>
<tr>
<td>Connecticut</td>
<td>185</td>
<td>4</td>
<td>Massachusetts</td>
<td>1,990</td>
<td>42</td>
<td>Utah</td>
<td>20</td>
<td>1</td>
</tr>
<tr>
<td>Delaware</td>
<td>8</td>
<td>1</td>
<td>Michigan</td>
<td>48</td>
<td>3</td>
<td>Virginia</td>
<td>73</td>
<td>2</td>
</tr>
<tr>
<td>Florida</td>
<td>2</td>
<td>2</td>
<td>Minnesota</td>
<td>75</td>
<td>5</td>
<td>Washington</td>
<td>614</td>
<td>5</td>
</tr>
<tr>
<td>Idaho</td>
<td>23</td>
<td>1</td>
<td>New Hampshire</td>
<td>6</td>
<td>1</td>
<td>Wisconsin</td>
<td>8</td>
<td>1</td>
</tr>
<tr>
<td>Illinois</td>
<td>18</td>
<td>2</td>
<td>New Jersey</td>
<td>46</td>
<td>4</td>
<td>Wyoming</td>
<td>38</td>
<td>1</td>
</tr>
<tr>
<td>Indiana</td>
<td>0.3</td>
<td>1</td>
<td>New York</td>
<td>380</td>
<td>13</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Iowa</td>
<td>13</td>
<td>1</td>
<td>North Carolina</td>
<td>41</td>
<td>5</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kansas</td>
<td>1</td>
<td>1</td>
<td>Ohio</td>
<td>34</td>
<td>6</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kentucky</td>
<td>2</td>
<td>1</td>
<td>Oregon</td>
<td>6</td>
<td>2</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Source: PwC/CB Insights MoneyTree™ Report Q2 2020

Note: Omitted states had no deals in the current quarter
Methodology

PwC (pwc.com/moneytree) and CB Insights (cbinsights.com) encourage you to review the methodology and definitions employed to better understand the numbers presented in this report. If you have any questions about the definitions or methodological principles used, we encourage you to reach out to CB Insights directly. Additionally, if you feel your firm has been underrepresented, please send an email to info@cbinsights.com and we can work together to ensure your firm’s investment data is up-to-date.

Rankings, e.g., top states and top sectors, are done by quarterly deal activity (that is, deal count for the given quarter).

What is included:

- Equity financings into emerging companies. Fundings must be to VC-backed companies, which are defined as companies that have received funding at any point from either: venture capital firms, corporate venture arms, or super angel investors.
- Fundings of private companies only. Funding rounds raised by public companies of any kind on any exchange (including Pink Sheets) are excluded from our numbers, even if they received investment by a venture firm(s).
- Only includes the investment made in the quarter for tranched investments. If a company does a second closing of its Series B round for $5M and previously had closed $2M in a prior quarter, only the $5M is reflected in our results.
- Round numbers reflect what has closed, not what is intended. If a company indicates the closing of $5M out of a desired raise of $15M, our numbers reflect only the amount which has closed.
- Only verifiable fundings are included. Fundings are verified via (1) various federal and state regulatory filings; (2) direct confirmation with firm or investor; (3) press release; or (4) credible media sources.
- Equity fundings to joint ventures and spinoffs/spinouts are included, given that they meet the VC-backed criteria.
- Geography note: Israel funding figures are classified in Asia.

What is excluded:

- No contingent funding. If a company receives a commitment for $20M subject to hitting certain milestones but first gets $8M, only the $8M is included in our data.
- No business development/R&D arrangements, whether transferable into equity now, later or never. If a company signs a $300M R&D partnership with a larger corporation, this is not equity financing nor is it from venture capital firms. As a result, it is not included.
- No buyouts, consolidations or recapitalizations. All three of these transaction types are commonly employed by private equity firms and are tracked by CB Insights. However, they are excluded for the purposes of this report.
- No private placements. These investments, also known as PIPEs (Private Investment in Public Equities), are not included even if made by a venture capital firm(s).
- No debt/loans of any kind (except convertible notes). Venture debt or any kind of debt/loan issued to emerging, startup companies, even if included as an additional part of an equity financing, is not included. If a company receives $3M with $2M from venture investors and $1M in debt, only the $2M is included in these statistics.
- No non-equity government funding. Grants or loans by the federal government, state agencies, or public-private partnerships to emerging, startup companies are not included.
- No fundings to subsidiaries of a larger parent corporation.

Source: PwC/CB Insights MoneyTree™ Report Q2 2020
This content is for general information purposes only, and should not be used as a substitute for consultation with professional advisors. **Data is current as of July 6, 2020.** PricewaterhouseCoopers and CB Insights have taken responsible steps to ensure that the information contained in the MoneyTree™ Report has been obtained from reliable sources. However, neither PwC nor CB Insights can warrant the ultimate validity of the data obtained in this manner. Results are updated periodically. Therefore, all data is subject to change at any time.

© 2020 PwC. All rights reserved. PwC refers to the US member firm or one of its subsidiaries or affiliates, and may sometimes refer to the PwC network. Each member firm is a separate legal entity. Please see www.pwc.com/structure for further details.